- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03648931
Microbicide/PrEP Acceptability Among Mothers and Male Partners in Africa (MAMMA)
Qualitative Assessment of Acceptability of Vaginal Ring (VR) and Oral Pre-exposure Prophylaxis (PrEP) Use During Pregnancy and Breastfeeding
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
MTN-041 is an exploratory study primarily designed to identify individual, interpersonal, social and cultural factors that may affect potential uptake of two safe and effective HIV prevention products, the monthly DPV VR and daily oral PrEP, in a vulnerable yet seldom-studied population, pregnant and breastfeeding women. MTN-041 will utilize FGDs and IDIs to elicit community and health professional perceptions about vaginal practices, sexual activity, use of medicines, and HIV risk during pregnancy or breastfeeding, including how these perceptions may affect pregnant and breastfeeding women's acceptability of using intravaginal products and oral medications like the DPV VR and Truvada oral tablet.
The MTN-041 study population will consist of HIV-uninfected women 18-40 years old who are currently or were recently (within two years) pregnant or breastfeeding, men aged 18 years or older whose partners are currently or were recently (within two years) pregnant or breastfeeding, grandmothers whose daughters or daughters-in-law are currently or were recently (within two years) pregnant or breastfeeding, and key informants (KIs), which include: health care professionals (HCPs), traditional birth attendants (TBAs), providers of family planning, antenatal, and traditional health services to women, providers of other social services to women, and community leaders.
Up to 60 men and women will be selected at each site for participation in this study, for a maximum total of 240 study participants. This includes up to 50 FGD participants (currently or recently pregnant or breastfeeding women, male partners of women who are currently or were recently pregnant or breastfeeding, and grandmothers with currently or recently pregnant or breastfeeding daughters/daughters-in-law) and up to 10 KIs selected at each site, for a maximum total of 200 FGD participants and 40 KIs enrolled across all sites.
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
-
Blantyre, Malawi
- Blantyre Clinical Research Site
-
-
-
-
-
Kampala, Oeganda
- Makerere University - Johns Hopkins University (MU-JHU) Research Collaboration Clinical Research Site
-
-
-
-
-
Harare, Zimbabwe
- Zengeza Clinical Research Site
-
-
-
-
-
Johannesburg, Zuid-Afrika
- Wits Reproductive Health and HIV Institute (WRHI) Clinical Research Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Able and willing to provide written informed consent in one of the study languages.
Able and willing to complete the required study procedures.
For currently or recently pregnant or breastfeeding women:
- Between the ages of 18 to 40 years old (inclusive) at Enrolment, verified per site standard operating procedures (SOPs).
Currently or recently (within two years) pregnant or breastfeeding (by self-report).
For male partners:
- Aged 18 years or older at Enrolment, verified per site SOPs.
Identifies as a primary sexual partner of a woman who is currently or was recently (within two years) pregnant or breastfeeding.
For grandmothers:
- Aged 18 years or older at Enrolment, verified per site SOPs.
Identifies as the maternal or paternal grandmother of a daughter or daughter-in-law who is currently or was recently (within two years) pregnant or breastfeeding.
Note: The term "daughter-in-law" includes women who are/were not married to their male partner during or after pregnancy.
For service provider KIs:
- Aged 18 years or older at Enrolment, verified per site SOPs.
- Currently working as a clinician (e.g., obstetrician, nurse, pharmacist, etc.), traditional care provider (e.g., TBA, healer, midwife, etc.), social service provider (e.g., social worker, family planning counselor, etc.) or community health worker in one of the study countries, verified per site SOPs.
Experienced in providing services to pregnant and/or breastfeeding women.
For community leader KIs:
- Aged 18 years or older at Enrolment, verified per site SOPs.
- Currently acting in a community leadership role (e.g., local chief, religious leader, etc.).
Exclusion Criteria:
- Has any condition that, in the opinion of the Investigator of Record (IoR)/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
- For currently or recently pregnant or breastfeeding women: known HIV-positive status, verified per recent health record (e.g., health passport, ante-natal book, HIV test card, or similar document) or by self-report if health record(s) not available.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
---|---|
Pregnant or Breastfeeding Women
No actual intervention is planned.
A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
|
No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures. In particular, the FGDs will focus on:
|
Male Partners
No actual intervention is planned.
A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
|
No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures. In particular, the FGDs will focus on:
|
Grandmothers
No actual intervention is planned.
A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
|
No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures. In particular, the FGDs will focus on:
|
Key Informants
No actual intervention is planned.
A single in-depth interview (IDI) will be conducted to assess study outcome measures.
|
No actual intervention is planned. A single in-depth interview (IDI) will be conducted to assess study outcome measures, focusing on the following topics:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Acceptability of VR during pregnancy and breastfeeding, including willingness to use the VR or support its use
Tijdsspanne: 3-6 months during Q2/Q3 2018
|
Focus group discussions and key informant in-depth interviews
|
3-6 months during Q2/Q3 2018
|
Acceptability of oral PrEP during pregnancy and breastfeeding, including willingness to use oral PrEP or support its use
Tijdsspanne: 3-6 months during Q2/Q3 2018
|
Focus group discussions and key informant in-depth interviews
|
3-6 months during Q2/Q3 2018
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Product preferences during pregnancy and breastfeeding
Tijdsspanne: 3-6 months during Q2/Q3 2018
|
Focus group discussions and key informant in-depth interviews
|
3-6 months during Q2/Q3 2018
|
Sexual activity and contraceptive use during pregnancy and breastfeeding
Tijdsspanne: 3-6 months during Q2/Q3 2018
|
Focus group discussions and key informant in-depth interviews
|
3-6 months during Q2/Q3 2018
|
Perceptions of HIV risk during pregnancy and breastfeeding
Tijdsspanne: 3-6 months during Q2/Q3 2018
|
Focus group discussions and key informant in-depth interviews
|
3-6 months during Q2/Q3 2018
|
Community beliefs and practices related to pregnancy and breastfeeding, including use of oral medications and intravaginal products
Tijdsspanne: 3-6 months during Q2/Q3 2018
|
Focus group discussions and key informant in-depth interviews
|
3-6 months during Q2/Q3 2018
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie stoel: Ariane van der Straten, PhD, MPH, Women's Global Health Imperative Program, RTI International
Publicaties en nuttige links
Algemene publicaties
- van der Straten A, Ryan JH, Reddy K, Etima J, Taulo F, Mutero P, Taylor J, Piper J, Musara P; MTN-041/MAMMA Study Team. Influences on willingness to use vaginal or oral HIV PrEP during pregnancy and breastfeeding in Africa: the multisite MAMMA study. J Int AIDS Soc. 2020 Jun;23(6):e25536. doi: 10.1002/jia2.25536.
- Flax VL, Hawley I, Ryan J, Chitukuta M, Mathebula F, Nakalega R, Seyama L, Taulo F, van der Straten A; MTN-041/MAMMA Study Team. After their wives have delivered, a lot of men like going out: Perceptions of HIV transmission risk and support for HIV prevention methods during breastfeeding in sub-Saharan Africa. Matern Child Nutr. 2021 Apr;17(2):e13120. doi: 10.1111/mcn.13120. Epub 2020 Dec 15.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- MTN-041
- UM1AI068633 (Subsidie/contract van de Amerikaanse NIH)
- UM1AI068615 (Subsidie/contract van de Amerikaanse NIH)
- UM1AI106707 (Subsidie/contract van de Amerikaanse NIH)
- 38161 (Andere identificatie: DAIDS)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op HIV-preventie
-
Bambino Gesù Hospital and Research InstituteVoltooidErnstige pediatrische obesitas (BMI > 97° pc -Volgens Centers for Disease Control and Prevention BMI Charts-) | Veranderde leverfunctietesten | Glykemische intolerantieItalië
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthWervingHiv | HIV-testen | Hiv-koppeling naar zorg | HIV-behandelingVerenigde Staten
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement; Centre Pasteur du Cameroun en andere medewerkersOnbekendHiv | HIV-niet-geïnfecteerde kinderen | Kinderen blootgesteld aan HIVKameroen
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationVoltooidPartner hiv-testen | HIV-counseling voor koppels | Paar communicatie | HIV-incidentieKameroen, Dominicaanse Republiek, Georgië, Indië
-
University of MinnesotaIngetrokkenHIV-infecties | Hiv/aids | Hiv | AIDS | Aids/Hiv probleem | AIDS en infectiesVerenigde Staten
-
Erasmus Medical CenterNog niet aan het wervenHIV-infecties | Hiv | HIV-1-infectie | HIV I-infectieNederland
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... en andere medewerkersWervingHiv | HIV-testen | Koppeling aan zorgZuid-Afrika
-
CDC FoundationGilead SciencesOnbekendHIV Pre-expositie profylaxe | Hiv-chemoprofylaxeVerenigde Staten
-
University of Maryland, BaltimoreIngetrokkenHiv | Niertransplantatie | HIV-reservoir | CCR5Verenigde Staten
-
Hospital Clinic of BarcelonaVoltooidIntegrase-remmers, HIV; HIV PROTEASE INHIBSpanje
Klinische onderzoeken op Focus Group Discussion (FGD)
-
University of OxfordShoklo Malaria Research UnitVoltooidVroeggeboorte | Te vroeg geboren babyThailand